LANTUS DIN 02294338
Health Canada record
| Active ingredient(s) | INSULIN GLARGINE 100 UNIT |
|---|---|
| Dosage form | Solution |
| Route | Subcutaneous |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | A10AE04 INSULIN GLARGINE |
| Original market date | 24-Sep-2007 |
| Current status date | 24-Sep-2007 |
| Source | Health Canada DPD |
Establishment licence of the holder
sanofi-aventis Canada Inc. — licence 101470, currently licensed, last inspection rating C (2026-02-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing INSULIN GLARGINE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02461528 | BASAGLAR | ELI LILLY CANADA INC | Solution | INSULIN GLARGINE 100 UNIT | Marketed |
| 02444844 | BASAGLAR | ELI LILLY CANADA INC | Solution | INSULIN GLARGINE 100 UNIT | Marketed |
| 02245689 | LANTUS | SANOFI-AVENTIS CANADA INC | Solution | INSULIN GLARGINE 100 UNIT | Marketed |
| 02251930 | LANTUS | SANOFI-AVENTIS CANADA INC | Solution | INSULIN GLARGINE 100 UNIT | Marketed |
| 02526441 | SEMGLEE | BIOCON SDN.BHD | Solution | INSULIN GLARGINE 100 UNIT | Marketed |
| 02478293 | SOLIQUA | SANOFI-AVENTIS CANADA INC | Solution | INSULIN GLARGINE 100 UNIT; LIXISENATIDE 33 MCG | Marketed |
| 02493373 | TOUJEO DOUBLESTAR | SANOFI-AVENTIS CANADA INC | Solution | INSULIN GLARGINE 300 UNIT | Marketed |
| 02441829 | TOUJEO SOLOSTAR | SANOFI-AVENTIS CANADA INC | Solution | INSULIN GLARGINE 300 UNIT | Marketed |
| 02444852 | BASAGLAR | ELI LILLY CANADA INC | Solution | INSULIN GLARGINE 100 UNIT | Cancelled Post Market |
| 02276410 | LANTUS | SANOFI-AVENTIS CANADA INC | Solution | INSULIN GLARGINE 100 UNIT | Cancelled Pre Market |
| 02280418 | LANTUS | SANOFI-AVENTIS CANADA INC | Solution | INSULIN GLARGINE 100 UNIT | Cancelled Pre Market |
International API supply for INSULIN GLARGINE
4 active FDA Drug Master Files.
Request a quote for LANTUS